Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
Open Access
- 27 July 2021
- journal article
- research article
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 10 (4) , 2271-2288
Abstract
Introduction Although the pneumococcal conjugate vaccine (PCV) has been introduced into select state immunization programs (SIPs) in India, many children remain unvaccinated. Recently, India’s Advisory Committee on Vaccines & Immunization Practices recommended PCV on the pediatric immunization schedule nationally. This study estimates the public health and economic impact of introducing either Pfizer’s 13-valent PCV (PCV13-PFE), GlaxoSmithKline’s 10-valent PCV (PCV10-GSK), or Serum Institute of India’s 10-valent PCV (PCV10-SII) into every pediatric SIP. Methods A model was developed to predict the disease cases, deaths, and costs associated with implementing PCV13-PFE, PCV10-GSK, or PCV10-SII in SIPs compared to no vaccination program across a 5-year period (2021–2025). State and national-level uptake rate and clinical and economic input parameters were collected from published literature. Disease outcomes included invasive pneumococcal disease, inpatient and outpatient pneumonia, and otitis media. Costs were estimated as vaccine-related costs and direct medical costs incurred to the healthcare system. Results were reported by individual state and aggregated nationally. Results Estimated over 5 years, implementing PCV13-PFE in SIPs could avert 12.1 million cases and save 626,512 lives among children under 5 years old compared to no vaccination. This corresponds to net national cost savings of over $1.0 billion. Both lower-valent PCVs are estimated to provide less economic savings than PCV13-PFE inclusive of vaccine-related costs. Compared with PCV13-PFE, implementing PCV10-GSK or PCV10-SII nationally is estimated to have a smaller public health impact, with PCV10-GSK averting 8.4 million cases (436,577 deaths) and PCV10-SII preventing 10.3 million cases (531,545 deaths) in India compared to no vaccination, respectively. Conclusion Implementation of PCV13-PFE throughout India is estimated to provide greater public health and economic benefits than PCV10-GSK or PCV10-SII SIPs. Our analysis highlights the substantial disease cases, deaths, and health system cost savings that may be realized from implementing PCV programs throughout India.Keywords
Funding Information
- Pfizer
This publication has 41 references indexed in Scilit:
- Reducing mortality from childhood pneumonia and diarrhoea: The leading priority is also the greatest opportunityJournal of Global Health, 2013
- Cost-Effectiveness of a 10- Versus 13-Valent Pneumococcal Conjugate Vaccine in Denmark and SwedenClinical Therapeutics, 2013
- Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The NetherlandsJournal of Infection, 2012
- Health and economic impact of rotavirus vaccination in GAVI-eligible countriesBMC Public Health, 2010
- Status of implementation of Framework Convention on Tobacco Control (FCTC) in Ghana: a qualitative studyBMC Public Health, 2010
- Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of ageCochrane Database of Systematic Reviews, 2009
- Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimatesThe Lancet, 2009
- Cost-Effectiveness of Pneumococcal Conjugate VaccineThe Pediatric Infectious Disease Journal, 2006
- Impact of the pneumococcal conjugate vaccine on otitis mediaThe Pediatric Infectious Disease Journal, 2003
- Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumoniaThe Pediatric Infectious Disease Journal, 2002